Biologics & Biosimilars Collective Intelligence Consortium (BBCIC)

Name

Biologics & Biosimilars Collective Intelligence Consortium (BBCIC)

Legal name

Biologics & Biosimilars Collective Intelligence Consortium (BBCIC)

Website

https://bbcic.org

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Pharmacoepidemiology Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO)

akta.pro secondary industry

Industry & Sector Research (Syndicated/Custom) (BPAHALAE)

Keywords

• Biosimilars research
• Real-world evidence
• Post-marketing surveillance
• Pharmacoepidemiology studies
• Biologics safety monitoring

Headquarters

HQ city

Alexandria

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Multi-Stakeholder Consortium Participation: BBCIC receives financial and in-kind commitments from pharmaceutical companies, managed care organizations, integrated delivery systems, pharmacy benefit management firms, research institutions, and patient advocacy organizations that participate as members supporting the consortium's research mission
2. Federal Research Grants: BBCIC receives FDA grants as cooperative agreements to conduct specific research projects including real-world data assessment for biosimilar regulatory decisions. Awarded $1.3 million in 2022 and $1.4 million in 2023
3. Institutional Support (AMCP Research Institute): BBCIC operates as part of the AMCP Research Institute, receiving institutional support and infrastructure from the Academy of Managed Care Pharmacy

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

Core offering

BBCIC operates a distributed research network that conducts post-marketing surveillance of biosimilars and corresponding novel biologics using de-identified real-world pharmacy, medical claims, and electronic health record data. It provides observational research studies, FDA-funded regulatory science research programs, utilization and outcomes analyses, and comparative safety and effectiveness research for healthcare stakeholders. Outputs are disseminated through peer-reviewed publications, conference presentations, and quarterly newsletters.

Product overview

BBCIC is a non-profit scientific research consortium that operates as a distributed research network dedicated to assessing biologics including biosimilars. The organization provides a research infrastructure enabling post-marketing surveillance of biosimilar safety and effectiveness through analysis of real-world data from healthcare organizations. BBCIC's core offerings include a distributed research network for conducting observational studies, FDA-funded regulatory science research programs, utilization and outcomes analyses, comparative safety and effectiveness studies, peer-reviewed publications, and educational resources on biologics and biosimilars. The consortium functions as a scientific research platform rather than a traditional software product, offering collaborative research services to healthcare stakeholders including managed care organizations, integrated delivery systems, pharmacy benefit management firms, research institutions, and pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Distributed Research Network for Biologics Surveillance A distributed research network infrastructure that enables multi-site observational analyses of biologics and biosimilars while raw data remains under source control at member organizations. Built on common data models aligned with the FDA Sentinel Initiative, it serves pharmaceutical companies, managed care organizations, PBMs, and research institutions collaborating on post-marketing surveillance.
• FDA-Funded Biosimilar Regulatory Science Research FDA cooperative agreement research programs focused on leveraging real-world data and real-world evidence to support regulatory decisions on biosimilars and interchangeable biosimilars, including evaluation of foreign real-world data from Italy and Denmark. Delivered for the U.S. Food and Drug Administration as the research sponsor.
• Utilization and Outcomes Analyses Periodic analyses of utilization patterns and patient outcomes for originator biologics and biosimilars within the distributed research network, covering therapeutic areas including oncology, inflammatory diseases, and diabetes. Delivered to consortium members and the broader scientific community.
• Comparative Safety and Effectiveness Studies Observational research studies comparing safety and effectiveness outcomes between reference biologics and biosimilar products using administrative claims and electronic health record data from the distributed research network. Outputs are published in peer-reviewed journals and presented at scientific conferences.

Quantifiable outcome

• 20 studies completed including utilization analyses, descriptive analyses, methods studies, and comparative safety/effectiveness research
• +3 more outcomes

Named customers13 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

24 partnerships are on record, tiered core.

• AbbViecoreStrategic or Co-development PartnerPharmaceutical company participating in BBCIC consortium providing financial and in-kind support for biosimilars post-marketing research activities since consortium founding
• AmgencoreStrategic or Co-development PartnerPharmaceutical company providing financial and in-kind commitments to BBCIC for biosimilars safety and effectiveness research
• PfizercoreStrategic or Co-development PartnerPharmaceutical company participating in BBCIC consortium supporting real-world evidence generation for biologics
• SandozcoreStrategic or Co-development PartnerPharmaceutical company providing financial and in-kind support for BBCIC research on biosimilars and interchangeability
• Boehringer Ingelheim PharmaceuticalscoreStrategic or Co-development PartnerPharmaceutical company participating in BBCIC consortium supporting post-marketing surveillance research
• MerckcoreStrategic or Co-development PartnerPharmaceutical company providing financial and in-kind support for BBCIC biosimilars research initiatives
• IQVIAcoreTechnology or IntegrationHealthcare data and analytics company providing research capabilities and expertise to BBCIC distributed research network
• CVS HealthcoreStrategic or Co-development PartnerHealthcare company providing clinical trial services and data resources to BBCIC through Aetna/CVS Health participation
• Express ScriptscoreStrategic or Co-development PartnerPharmacy benefit management firm providing data resources and research support to BBCIC consortium
• OptumcoreStrategic or Co-development PartnerHealth services and innovation company contributing data and research expertise to BBCIC network
• Harvard Pilgrim Health CarecoreStrategic or Co-development PartnerHealth plan providing research data and scientific expertise through Harvard Pilgrim Health Care Institute to BBCIC
• HealthPartnerscoreStrategic or Co-development PartnerIntegrated healthcare delivery system providing data and research capabilities to BBCIC distributed network
• Anthem/HealthCorecoreStrategic or Co-development PartnerHealth insurance company providing claims data and research support to BBCIC consortium
• Henry Ford Health SystemcoreStrategic or Co-development PartnerIntegrated health system contributing clinical data and research capabilities to BBCIC
• Kaiser Permanente of WashingtoncoreStrategic or Co-development PartnerIntegrated delivery system providing electronic health record and claims data to BBCIC network
• ApobiologixcoreStrategic or Co-development PartnerBiosimilar development company participating in BBCIC consortium to support biosimilars monitoring research (joined January 2017)
• Patient Advocate FoundationcoreStrategic or Co-development PartnerPatient advocacy organization providing perspective and support for BBCIC research on patient outcomes
• Arthritis FoundationcoreStrategic or Co-development PartnerPatient advocacy organization supporting BBCIC initiatives related to arthritis treatments and biologics
• Hematology Oncology Pharmacy AssociationcoreStrategic or Co-development PartnerProfessional pharmacy organization providing oncology expertise to BBCIC research activities
• University of VeronacoreStrategic or Co-development PartnerInternational academic partner in Italy collaborating on FDA Grant 2 to evaluate foreign real-world data for biosimilar interchangeability studies
• University of Southern DenmarkcoreStrategic or Co-development PartnerInternational academic partner providing Danish real-world data for cross-country comparison in biosimilars research under FDA Grant 2
• PearlDiver TechnologiescoreTechnology or IntegrationHealthcare database company providing claims data assets for BBCIC research including bevacizumab and trastuzumab utilization analyses
• Carelon ResearchcoreStrategic or Co-development PartnerResearch organization leading BBCIC's Biosimilar Access and Utilization study using Healthcare Integrated Research Database (HIRD)
• FDA - U.S. Food and Drug AdministrationcoreStrategic or Co-development PartnerRegulatory agency providing grant funding (cooperative agreements) to support BBCIC research on using real-world data for biosimilars regulatory decisions. Awarded $1.3M (2022) and $1.4M (2023) grants

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• IQVIA: Global leader in real-world evidence, clinical research, and healthcare data analytics serving pharmaceutical manufacturers and managed care organizations. Comparable to BBCIC because it is both a BBCIC consortium member and the dominant commercial provider of pharmacoepidemiology and RWE services that compete for similar pharma and payer budgets.
• Optum (OptumLabs / Optum Health): Large US healthcare data and analytics platform providing real-world evidence, claims datasets, and research services to pharma and payers. Comparable because Optum is both a BBCIC consortium member and operates one of the largest US commercial RWE research networks that competes for biologics and biosimilars research mandates.

Others

• FDA Sentinel Initiative: US government national active surveillance system using distributed claims and EHR data for post-market drug safety. Comparable because BBCIC explicitly applies 'scientific and analytic methods similar to the FDA Sentinel initiative,' making Sentinel both the methodological standard and a potential public alternative for similar regulatory-grade RWE.

Direct peers

• HealthCore (Anthem/HealthCore): Health services research subsidiary of Elevance Health conducting real-world outcomes research using administrative claims and EHR data for biopharma and biosimilar manufacturers. Directly comparable as both a BBCIC consortium partner (via Anthem/HealthCore) and a peer research organization running parallel distributed-network pharmacoepidemiology studies on biologics.
• Harvard Pilgrim Health Care Institute: Health services and pharmacoepidemiology research institute operating within the FDA Sentinel Innovation Center and providing real-world drug safety analyses. Comparable because it is both a BBCIC data partner and a peer academic institution conducting distributed-network post-market biologic and biosimilar surveillance research.
• Carelon Research (formerly HealthCore/Evernorth): Real-world evidence and health economics research organization conducting claims and EHR-based studies across therapeutic areas including oncology and immunology. Comparable as both a BBCIC data/analytics partner and a peer research provider producing biologics and biosimilars utilization and outcomes analyses for pharma and payer clients.

Emerging players

• Observational Health Data Sciences and Informatics (OHDSI): Multi-stakeholder, open-science collaborative producing reproducible observational analyses across a global distributed research network using the OMOP common data model. Directly comparable to BBCIC in network architecture, OMOP-style common data model approach, and disease-area outcomes research, serving overlapping research institutions.
• PearlDiver Technologies: Healthcare claims database analytics company providing research-ready data assets to academic and industry researchers studying biologics and biosimilars. Comparable because PearlDiver is both a BBCIC data partner and a peer analytics vendor used by the same customers (manufacturers, PBMs) for similar utilization analyses.
• Truveta: Health system-owned real-world data platform aggregating electronic health records across US provider systems to deliver de-identified health data for research and biopharma customers. Comparable as a newer distributed research network applying common data models to post-market drug effectiveness and biosimilar-related research with similar target customers.
• Flatiron Health: Technology-focused oncology real-world data and evidence company supporting biopharma research using de-identified EHR data. Comparable as a peer RWE provider focused specifically on oncology biologics and biosimilars—an important disease area for BBCIC—and serving the same pharmaceutical manufacturer customer segment.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bbcic

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biologics & Biosimilars Collective Intelligence Consortium (BBCIC)